SPTX Stock Forecast & Price Target

Seaport Therapeutics is supported by a differentiated Glyph platform that improves oral bioavailability by bypassing first-pass metabolism, with GlyphAllo showing more than 9x higher oral exposure and GlyphAgo delivering a 6.8x bioavailability increase versus their native compounds. Recent Phase 1 driving-simulation data strengthened the investment case by showing no next-morning driving impairment or serious adverse events for GlyphAllo, while the company’s lead programs remain on track for multiple catalysts through 2028, including BUOY-1 top-line data in 1H27. The outlook is further reinforced by massive addressable markets in MDD and GAD, peak annual sales estimates of about $7B for GlyphAllo and $1.3B for GlyphAgo, and gross margins expected to exceed 95% given the small-molecule, high-IP model.

Seaport Therapeutics is a relatively young clinical-stage company with no operating history, making its prospects highly uncertain and dependent on successful development of GlyphAllo and GlyphAgo, which still face major clinical and regulatory hurdles. Although the DCF framework assumes a $2.74B enterprise value, $3.27B firm value, and about $427M in cash as of mid-2026, that valuation rests on only 60% approval for GlyphAllo and 40% for GlyphAgo, while negative trial outcomes, FDA delays, and long-term dilution remain meaningful risks. The bear case is reinforced by weak market proof in psychiatry, where only two anxiety medicines were approved in the United States from 2008 to 2024, and by reimbursement pressure as CMS, PBMs, and drug-pricing controls could limit uptake and economics.